Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

ÀڱðæºÎ¾Ï ¹× »óÇdz»¾Ï Á¶Á÷¿¡¼­ÀÇ ÀÎÀ¯µÎÁ¾¹ÙÀÌ·¯½º¿Í Cyclooxygenase 2 °ú¹ßÇöÀÇ »ó°ü°ü°è

Relation between HPV and cyclooxygenase 2 overexpression in cervical carcinoma in situ and carcinoma

´ëÇÑ»êºÎÀΰúÇÐȸÁö 2008³â 51±Ç 8È£ p.866 ~ 873
ÃÖÀ±¼® ( Choi Youn-Seok ) - ´ë±¸°¡Å縯´ëÇб³ Àǰú´ëÇÐ »êºÎÀΰúÇб³½Ç

¿ÀÈÆ±Ô ( Oh Hoon-Kyu ) - ´ë±¸°¡Å縯´ëÇб³ Àǰú´ëÇÐ º´¸®Çб³½Ç
±èȫŠ( Kim Hong-Tae ) - ´ë±¸°¡Å縯´ëÇб³ Àǰú´ëÇÐ ÇØºÎÇб³½Ç
±èÁÖÇö ( Kim Ju-Hyun ) - ´ë±¸°¡Å縯´ëÇб³ Àǰú´ëÇÐ »êºÎÀΰúÇб³½Ç
ÀÌżº ( Lee Tae-Sung ) - ´ë±¸°¡Å縯´ëÇб³ Àǰú´ëÇÐ »êºÎÀΰúÇб³½Ç
ÇÑÄ¡µ¿ ( Han Chi-Dong ) - ´ë±¸°¡Å縯´ëÇб³ Àǰú´ëÇÐ »êºÎÀΰúÇб³½Ç

Abstract

¸ñÀû: ÀڱðæºÎ¾Ï ¹× ÀڱðæºÎ »óÇdz»¾Ï¿¡¼­ ÀÎÀ¯µÎÁ¾¹ÙÀÌ·¯½º (HPV)¿Í cyclooxygenase 2 (COX-2) ¹ßÇö°úÀÇ »ó°ü °ü°è¸¦ ¾Ë¾Æ º¸°íÀÚ ÇÏ¿´´Ù.

¹æ¹ý: °¢°¢ 14¸í¾¿ÀÇ ÀڱðæºÎ »óÇdz»¾Ï, ÀڱðæºÎ¾Ï ȯÀÚÀÇ ÀڱðæºÎ Á¶Á÷°ú, ´ëÁ¶±ºÀ¸·Î´Â ÀڱñÙÁ¾À¸·Î ÀÚ±ÃÀûÃâ¼úÀ» ¹ÞÀº 14¸íÀÇ È¯ÀÚµéÀÇ ÀڱðæºÎ Á¶Á÷À» ÀÌ¿ëÇÏ¿´´Ù. ÀÎÀ¯µÎÁ¾¹ÙÀÌ·¯½º °ËÃâ¿¡´Â ÁßÇÕÈ¿¼Ò¿¬¼â¹ÝÀÀÀ» ÀÌ¿ëÇÏ¿´°í, COX-2 °ËÃâ¿¡´Â ¸é¿ªÁ¶Á÷È­ÇÐÀû ¿°»öÀ» ÀÌ¿ëÇÏ¿´´Ù.

°á°ú: °íÀ§Ç豺ÀÇ ÀÎÀ¯µÎÁ¾¹ÙÀÌ·¯½º °¨¿°Àº ´ëÁ¶±º¿¡ ºñÇØ »óÇdz»¾Ï°ú ÀڱðæºÎ¾Ï¿¡¼­ ÇöÀúÈ÷ ¸¹ÀÌ °ËÃâµÇ¾ú´Ù [»óÇdz»¾Ï:11¿¹ (78.6%), ÀڱðæºÎ¾Ï: 14¿¹ (100%), ´ëÁ¶±º: 1¿¹ (7.1%), P-value<0.001]. COX-2ÀÇ ¹ßÇö °­µµ´Â ´ëÁ¶±ºº¸´Ù »óÇdz»¾ÏÀ̳ô¾Ò°í (P=0.037), ÀڱðæºÎ¾ÏÀÌ »óÇdz»¾Ïº¸´Ù ´õ ³ô¾Ò´Ù (P=0.002). ÀÎÀ¯µÎÁ¾¹ÙÀÌ·¯½º°¡ °ËÃâµÇÁö ¾Ê¾Ò´ø »óÇdz»¾Ï 3¿¹¿¡¼­´Â ¹ÙÀÌ·¯½º°¡ °ËÃâµÇ¾ú´ø ³ª¸ÓÁö »óÇdz»¾Ï¿¡ ºñÇÏ¿© COX-2ÀÇ ¹ßÇöÀÌ ÇöÀúÈ÷ ³·°Ô ³ªÅ¸³µ´Ù (P=0.013). COX-2ÀÇ ¹ßÇöÁ¤µµ¿Í ÀÎÀ¯µÎÁ¾¹ÙÀÌ·¯½º°¨¿°°ú´Â À¯ÀÇÇÑ »ó°ü°ü°è¸¦ º¸¿´À¸³ª (P<0.001), ´Ùº¯·® ºÐ¼®¿¡¼­´Â Á¤»ó Á¶Á÷¿¡¼­ »óÇdz»¾Ï, ħÀ±¾ÏÀ¸·ÎÀÇ ÁøÇุÀÌ COX-2 °ú¹ßÇö¿¡ µ¶¸³ÀûÀ¸·Î ¿µÇâÀ» ÁÖ´Â ÀÎÀÚ¿´´Ù.

°á·Ð: COX-2ÀÇ °ú¹ßÇö¿¡´Â Á¤»óÁ¶Á÷¿¡¼­ ħÀ±¾ÏÀ¸·ÎÀÇ ÁøÇàÁ¤µµ°¡ °íÀ§Çè ÀÎÀ¯µÎÁ¾¹ÙÀÌ·¯½º°¨¿°º¸´Ù ´õ Áß¿äÇÑ ¿äÀÎÀ¸·Î ÃßÁ¤µÈ´Ù.

Objective: The aim of this study was to identify the relation between HPV infection and cyclooxygenase 2 (COX-2) overexpression in cervical carcinoma in situ (CIS) and carcinoma.

Methods: Fourteen patients with CIS, 14 patients with invasive cervical carcinoma, and 14 patients with myoma as control were enrolled. Polymerase chain reaction was used to detect high risk types of HPV, and immunohistochemistry was used to detect COX-2 expression.

Results: The frequencies of high risk types of HPV infections in CIS or carcinoma were significantly higher than control [CIS: 11 (78.6%), carcinoma: 14 (100%), control: 1 (7.1%), P-value<0.001]. COX-2 expressions in CIS were higher than control (P=0.037), and those in carcinoma were higher than CIS (P=0.002). Three patients with CIS did not show HPV infection and showed lower COX-2 expression than the other patients with HPV infection in CIS group (P=0.013). There was strong correlation between COX-2 expression and HPV infection (P<0.001). However, in multivariate analysis, disease progression from normal to invasive carcinoma was the only independent factor to affect COX-2 overexpression.

Conclusion: Disease progression from normal to invasive carcinoma might be more important factor to affect COX-2 overexpression than high risk types of HPV infection.

Ű¿öµå

½ÃŬ·Î¿Á½Ã°Ô³ª¾ÆÁ¦ 2;ÀڱðæºÎ¾Ï;ÀÎÀ¯µÎÁ¾¹ÙÀÌ·¯½º
Cyclooxygenase 2;COX-2;Uterine cervical cancer;HPV;Human papilloma virus
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
  
µîÀçÀú³Î Á¤º¸
KCI
KoreaMed
KAMS